Lucintel's latest market report analyzed that vaccine adjuvant provides attractive opportunities in infectious disease and cancer applications. The vaccine adjuvant market is expected to reach $2.6 billion by 2028 with a CAGR of 12.6%. In this market, adjuvant emulsion is the largest segment by product, whereas infectious disease is largest by application. Download Brochure of this report by...